|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes显示文摘AIM To review Hepatitis C virus(HCV) prevalence and genotypes distribution worldwide.METHODS We conducted a systematic study which represents one of the most comprehensive effort to quantify global HCV epidemiology,using the best available published data between 2000 and 2015 from 138 countries(about 90% of the global population),grouped in 20 geographical areas(with the exclusion of Oceania),as defined by the Global Burden of Diseases project(GBD). Countries for which we were unable to obtain HCV genotype prevalence data were excluded from calculations of regional proportions,although their populations were included in the total population size of each region when generating regional genotype prevalence estimates.RESULTS Total global HCV prevalence is estimated at 2.5%(177.5 million of HCV infected adults),ranging from 2.9% in Africa and 1.3% in Americas,with a global viraemic rate of 67%(118.9 million of HCV RNA positive cases),varying from 64.4% in Asia to 74.8% in Australasia. HCV genotype 1 is the most prevalent worldwide(49.1%),followed by genotype 3(17.9%),4(16.8%) and 2(11.0%). Genotypes 5 and 6 are responsible for the remaining < 5%. While genotypes 1 and 3 are common worldwide,the largest proportion of genotypes 4 and 5 is in lower-income countries. Although HCV genotypes 1 and 3 infections are the most prevalent globally(67.0% if considered together),other genotypes are found more commonly in lowerincome countries where still account for a significant proportion of HCV cases.CONCLUSION A more precise knowledge of HCV genotype distribution will be helpful to best inform national healthcare models to improve access to new treatments. | Arnolfo Petruzziello Samantha Marigliano Giovanna Loquercio Anna Cozzolino Carmela Cacciapuoti | 2016 | World Journal of Gastroenterology2016，22，34： | 69 |
| 2 | Silybin and the liver: From basic research to clinical practice显示文摘Herbal products are increasingly used, mainly in chronic liver disease. Extracts of milk thistle, Silymarin and silybin, are the most prescribed natural compounds, with different indications, but with no definitive results in terms of clinical efficacy. This review analyzes the available studies on the effects of the purified product silybin, both as a free and a conjugated molecule, on liver cells or on experimentally induced liver damage, and in patients with liver disease. We searched PUBMED for articles pertaining to the in vitro and in vivo effects of silybin, its antifibrotic, anti-inflammatory, and antioxidant properties, as well as its metabolic effects, combined with the authors’ own knowledge of the literature. Results indicate that the bioavailability of silybin phytosome is higher than that of silymarin and is less influenced by liver damage; silybin does not show significant interactions with other drugs and at doses < 10 g/d has no significant side effects. Experimental studies have clearly demonstrated the antifibrotic, antioxidant and metabolic effects of silybin; previous human studies were insufficient for confirming the clinical efficacy in chronic liver disease, while ongoing clinical trials are promising. On the basis of literature data, silybin seems a promising drug for chronic liver disease. | Carmela Loguercio Davide Festi | 2011 | World Journal of Gastroenterology2011，17，18： | 26 |
| 3 | Serum uric acid as a prognostic marker in the setting of advanced vascular disease: a prospective study in the elderly显示文摘BackgroundMany 流行病学的研究分析在 hyperuricemia 和心血管的结果之间的关系。这观察未来的研究调查有在一张老人口的不利心血管的事件和死亡的尿酸(SUA ) 层次由百和 76 个老病人由先进动脉粥样硬化影响了的先进 atherosclerosis.MethodsTwo 影响了的浆液的协会(217 男性和 59 女性;71.2 ±7.8 年) 被包括。所有病人为心血管的疾病,癌症,肥胖和传统的风险因素的历史被估计。病人们为约 31 ± 被跟随;11 个月。主要事件在后续,定义同样心肌的梗塞,服的局部缺血,心肌或外部的 revascularization 和 death.ResultsMean SUA 期间被记录水平是 5.47 ±1.43 mg/dL;然后,我们进一步在二个组划分了人口,根据中部的价值(5.36 mg/dL ) 。在期间一中部列在后面在上面 31,月(5 ~ 49 个月) , 66 个心血管的事件, 9 个致命的心血管的事件和 14 癌症相关的死亡发生了。有增加的 SUA 水平的病人介绍了全部的心血管的事件的更高重要的发生(HR:1.867, P = 0.014, 95% CI:1.134-3.074 ) 。一样的病人显示出癌症相关的死亡的重要增加的风险(HR:4.335, P = 0.025, 95% CI:1.204-15.606 ).ConclusionsIncreased SUA 层次独立地并且显著地与心血管的事件的风险被联系,癌症在外部 vasculopathy 影响的主要老的病人的一张人口联系了死亡。 | Giuseppe Di Stolfo Sandra Mastroianno Domenico Rosario Potenza Giovanni De Luca Carmela d'Arienzo Michele Antonio Pacilli Mario Fanelli Aldo Russo Raffaele Fanelli | 2015 | Journal of Geriatric Cardiology2015，12，5： | 20 |
| 4 | Efficacy of rituximab in gastric diffuse large B cell lymphoma patients显示文摘AIM:To evaluate retrospectively the efficacy of rituximab plus chemotherapy in gastric diffuse large B cell lymphoma(DLBCL).METHODS:Sixty patients(median age:58 years)with histologically confirmed gastric DLBCL treated at four Italian institutions between 2000 and 2007,were included in this analysis.Patients were selected by stage (Ⅰ-Ⅳ,Lugano staging system),European Cooperative Oncology Group performance status(0-2)and treatment strategies.Treatment strategies were chemotherapy alone(group A,n=30)[scheduled as cyclophosphamide,doxorubicin,vincristine and prednisone (CHOP)and CHOP-like],and chemotherapy combined with rituximab(group B,n=30).The primary end point of the study was complete response(CR)rate;the secondary end points were disease-free survival (DFS)at 5 years and overall survival(OS).RESULTS:Median follow-up was 62 mo(range:31102 mo).We observed a significant difference between the two groups(A vs B)in terms of CR[76.6%(23/30) vs 100%,P=0.04)and DFS at 5 years[73.3%(22/30) vs 100%,P=0.03).To date,19 group A(63.3%) patients are alive and 11 have died,while all group B patients are alive.No significant differences in toxicity were observed between the two groups.CONCLUSION:Rituximab in combination with chemotherapy improves CR rate,DFS and OS.Further prospective trials are needed to confirm our results. | Davide Leopardo Giuseppe Di Lorenzo Amalia De Renzo Piera Federico Serena Luponio Carlo Buonerba Elide Matano Gerardina Merola Martina Imbimbo Enzo Montesarchio Antonio Rea Maria Carmela Merola Sabino De Placido Giovannella Palmieri | 2010 | World Journal of Gastroenterology2010，16，20： | 19 |
| 5 | High circulating D-dimers are associated with ascites and hepatocellular carcinoma in liver cirrhosis显示文摘AIM: To measure plasma D-dimer levels in cirrhotic patients with and without ascites, assessing the effect of ascites resolution in D-dimer concentration. METHODS: Seventy consecutive cirrhotic patients (M = 44, F = 26, mean age 65 years, SD ± 13), observed from October 2005 to March 2006 were enrolled. Circulating D-dimer levels were measured using a latex-enhanced, immunoturbidimetric test. In patients with ascites (n = 42) the test was repeated after ascites resolution. RESULTS: Ascites was present in 42 patients (group A) and absent in 28 (group B). Group A patients had more advanced liver disease. Hepatocellular carcinoma (HCC) was diagnosed in 14 patients and was more frequent in group B. Above normal range D-dimers were found in 45/70 patients. High D-dimers were more frequent in group A than in group B (P = 0.001). High D-dimers were associated with presence of HCC (P = 0.048) only in group B. After ascites resolution, obtained in all patients, mean D-dimer values decreased in those 34 patients with high basal levels (P = 0.007), returning to normal in 17. CONCLUSION: In patients with liver cirrhosis, ascites and HCC are the main factors associated with increased fibrinolytic activity. | Aldo Spadaro Vincenza Tortorella Carmela Morace Agostino Fortiguerra Paola Composto Caterina Bonfiglio Angela Alibrandi Carmelo Luigiano Giuseppe De Caro Antonino Ajello Oscar Ferraù Maria Antonietta Freni | 2008 | World Journal of Gastroenterology2008，14，10： | 19 |
| 6 | Ultrasound detection of abdominal lymphadenomegaly in subjects with hepatitis C virus infection and persistently normal transaminases:a predictive index of liver histology severity显示文摘UltrasounddetectionofabdominallymphadenomegalyinsubjectswithhepatitisCvirusinfectionandpersistentlynormaltransaminases:apredi... | Maurizio Soresi, Antonio Carroccio, Giulio Bonfissuto, Vincenzo Agate 1, Carmela Magliarisi, Federico Aragona 1, Massimo Levrero 2, Alberto Notarbartolo and Giuseppe Montalto Cattedra di Medicina Interna, 1Istituto di Anatomia Patologica, Univ | 1998 | World Journal of Gastroenterology1998，4，3： | 15 |
| 7 | Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease(NAFLD)has become the most common liver disorder in Western countries and is increasingly being recognized in developing nations.Fatty liver disease encompasses a spectrum of hepatic pathology,ranging from simple steatosis to non-alcoholic steatohepatitis,cirrhosis,hepatocellular carcinoma and end-stage liver disease.Moreover,NAFLD is often associated with other metabolic conditions,such as diabetes mellitus type 2,dyslipidemia and visceral obesity.The most recent guidelines suggest the management and treatment of patients with NAFLD considering both the liver disease and the associated metabolic co-morbidities.Diet and physical exercise are considered the first line of treatment for patients with NAFLD,but their results on therapeutic efficacy are often contrasting.Behavior therapy is necessary most of the time to achieve a sufficient result.Pharmacological therapy includes a wide variety of classes of molecules with different therapeutic targets and,often,little evidence supporting the real efficacy.Despite the abundance of clinical trials,NAFLD therapy remains a challenge for the scientific community,and there are no licensed therapies for NAFLD.Urgently,new pharmacological approaches are needed.Here,we will focus on the challenges facing actual therapeutic strategies and the most recent investigated molecules. | Alessandro Federico Claudio Zulli Ilario de Sio Anna Del Prete Marcello Dallio Mario Masarone Carmela Loguercio | 2014 | World Journal of Gastroenterology2014，20，45： | 10 |
| 8 | Personality traits and emotional patterns in irritable bowel syndrome显示文摘The review focuses on those personality traits(neuroticism, extraversion, openness to experience, agreeableness, and conscientiousness), constructs(alexithymia and distressed- Type D personality) and emotional patterns(negative and positive) that are of particular concern in health psychology, with the aim to highlight their potential role on the pathogenesis, onset, symptom clusters, clinical course, and outcome of irritable bowel syndrome(IBS). Personality traits and emotional patterns play key roles in affecting autonomic, immune, inflammatory, and endocrine functions, thus contributing not only to IBS clinical expression and symptomatic burden, but also to disease physiopathology. In this sense, psychological treatments should address those personality traits and emotional features that are constitutive of, and integral to IBS. The biopsychosocial model of illness applied to IBS acknowledges the interaction between biological, psychological, environmental, and social factors in relation to pain and functional disability. A holistic approach to IBS should take into account the heterogeneous nature of the disorder, and differentiate treatments for different types of IBS, also considering the marked individual differences in prevalent personality traits and emotional patterns. Beyond medications, and lifestyle/dietary interventions, psychological and educational treatments may provide the optimal chance of addressing clinical symptoms, comorbid conditions, and quality of life in IBS patients. | Maria Rosaria A Muscatello Antonio Bruno Carmela Mento Gianluca Pandolfo Rocco A Zoccali | 2016 | World Journal of Gastroenterology2016，22，28： | 7 |
| 9 | Nutritional modulation of the inflammatory response in inflammatory bowel disease-From the molecular to the integrative to the clinical显示文摘Nutrient deficiencies are common in patients with inflammatory bowel disease (IBD). Both total parenteral and enteral nutrition provide important supportive therapy for IBD patients, but in adults these are not useful for primary therapy. Dietary intervention with omega-3 polyunsaturated fatty acids contained in fish oil may be useful for the care of IBD patients, and recent studies have stressed the role of PPAR on NFκB activity on the potential beneficial effect of dietary lipids on intestinal function. | Gary E Wild Laurie Drozdowski Carmela Tartaglia M Tom Clandinin Alan BR Thomson | 2007 | World Journal of Gastroenterology2007，13，1： | 6 |
| 10 | Eradication of Helicobacter pylori infection:Which regimen first?显示文摘Helicobacter pylori(H.pylori)is a well-known human pathogen that plays an essential role in the pathogenesis of chronic gastritis,peptic ulcer disease,and gastric malignancies.Although H.pylori is susceptible to several antimicrobials,this infection has proven challenging to cure because of the increasing prevalence of bacterial strains that are resistant to the most commonly used antimicrobials,particularly clarithromycin.An effective(i.e.,>90%)first-line therapy is mandatory for avoiding supplementary treatments and testing,and more importantly for preventing the development of secondary resistance.This study reviews the recent literature on first-line therapies forH.pylori.The eradication rates following standard triple therapy(a proton pump inhibitor plus amoxicillin and clarithromycin)for H.pylori infection are declining worldwide.Several first-line strategies have been proposed to increase the eradication rate,including extending the treatment duration to 14 d,the use of a four-drug regimen(bismuth-containing quadruple,sequential,and concomitant treatments),and the use of novel antibiotics,such as fluoroquinolones.However,the ef5ficacy of these regimens is controversial.A first-line eradication regimen should be based on what works best in a defined geographical area and must take into account the prevalence of antimicrobial resistance in that region. | Alessandro Federico Antonietta Gerarda Gravina Agnese Miranda Carmela Loguercio Marco Romano | 2014 | World Journal of Gastroenterology2014，20，3： | 6 |
| 11 | Ceruloplasmin-ferroportin system of iron traffic in vertebrates显示文摘Safe trafficking of iron across the cell membrane is a delicate process that requires specific protein carriers. While many proteins involved in iron uptake by cells are known, only one cellular iron export protein has been identified in mammals: ferroportin(SLC40A1). Ceruloplasmin is a multicopper enzyme endowed with ferroxidase activity that is found as a soluble isoform in plasma or as a membrane-associated isoform in specific cell types. According to the currently accepted view, ferrous iron transported out of the cell by ferroportin would be safely oxidized by ceruloplasmin to facilitate loading on transferrin. Therefore, the ceruloplasminferroportin system represents the main pathway for cellular iron egress and it is responsible for physiological regulation of cellular iron levels. The most recent findings regarding the structural and functional features of ceruloplasmin and ferroportin and their relationship will be described in this review. | Giovanni Musci Fabio Polticelli Maria Carmela Bonaccorsi di Patti | 2014 | World Journal of Biological Chemistry2014，5，2： | 6 |
| 12 | 多器官床旁即时超声在新型冠状病毒肺炎中的应用:国际专家共识显示文摘新型冠状病毒肺炎(简称新冠肺炎,COVID-19)自首次报道以来,已造成全球超一亿人感染,给各国的公共卫生体系造成了巨大威胁。新冠肺炎的临床表现以呼吸系统体征和症状为主,80%的患者症状轻微,约5%为危重症患者,常表现为急性呼吸窘迫综合征(ARDS)。前期,由于缺乏相关研究,面对日益紧迫的临床困境,医务人员不得不借鉴采取一些经验性措施以应对疫情。 | 王臻(译) Arif Hussain Gabriele Via Lawrence Melniker Alberto Goffi Guido Tavazzi Luca Neri Tomas Villen Richard Hoppmann Francesco Mojoli Vicki Noble Laurent Zieleskiewicz Pablo Blanco Irene W.Y.Ma Mahathar Abd.Wahab Abdulmohsen Alsaawi Majid AI Salamah Martin Balik Diego Barca Karim Bendjelid Belaid Bouhemad Pablo Bravo-Figueroa Raoul Breitkreutz Juan Calderon Jim Connolly Roberto Copetti Francesco Corradi Anthony J.Dean AndréDenault Deepak Govil Carmela Graci Young-Rock Ha Laura Hurtado Toru Kameda Michael Lanspa Christian B Laursen Francis Lee Rachel Liu Massimiliano Meineri Miguel Montorfano Peiman Nazerian Bret P.Nelson Aleksandar N.Neskovic Ramon Nogue Adi Osman JoséPazeli Elmo Pereira-Junior Tomislav Petrovic Emanuele Pivetta Jan Poelaert Susanna Price Gregor Prosen Shalim Rodriguez Philippe Rola Colin Royse Yale Tung Chen Mike Wells Adrian Wong Wang Xiaoting Wang Zhen Yaseen Arabi | 2021 | 中国呼吸与危重监护杂志2021，20，2： | 5 |
| 13 | Ovarian cancer standard of care: are there real alternatives?显示文摘Ovarian cancer remains a major issue for gynecological oncologists, and most patients are diagnosed when the disease is already advanced with a poor chance of survival. Debulking surgery followed by platinum-taxane chemotherapy is the current standard of care, but based on several different strategies currently under evaluation, some encouraging data have been published in the last 4 to 5 years. This review provides a state-of-the-art overview of the available alternatives to conventional treatment and the most promising new combinations. For example, neoadjuvant chemotherapy does not seem to be inferior to primary debulking. Despite its outcome improvements, intraperitoneal chemotherapy struggles for acceptance due to the heavy toxicity. Dose-dense chemotherapy, after showing an impressive efficacy in Asian populations, has not produced equal results in a European cohort, and the results of alternative platinum doublets are not superior to those of carboplatin and paclitaxel. In this setting, adherence to a maintenance therapy after first-line treatment and multiple(primarily antiangiogenic) agents appears to be effective. Although many questions, including the duration of maintenance treatment and the use of bevacizumab beyond progression, remain unanswered, new biologic agents, such as poly(ADP-ribose) polymerase(PARP) inhibitors, nintedanib, and mitogen-activated protein/extracellular signal-regulated kinase(MEK) inhibitors, have emerged as potential therapeutic options in the very near future. Based on the multiplicity of available strategies, the histological and molecular features of the tumor, in addition to patient's clinical condition and disease state, continue to gain importance in guiding treatment choices. | Chiara Della Pepa Giuseppe Tonini Carmela Pisano Marilena Di Napoli Sabrina Chiara Cecere Rosa Tambaro Gaetano Facchini Sando Pignata | 2015 | Chinese Journal of Cancer2015，34，1： | 5 |
| 14 | Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease显示文摘Rates of non-alcoholic fatty liver disease(NAFLD) are increasing worldwide in tandem with the metabolic syndrome, with the progressive form of disease, nonalcoholic steatohepatitis(NASH) likely to become the most common cause of end stage liver disease in the not too distant future. Lifestyle modification and weight loss remain the main focus of management in NAFLD and NASH, however, there has been growing interest in the benefit of specific foods and dietary components on disease progression, with some foods showing protective properties. This article provides an overview of the foods that show the most promise and their potential benefits in NAFLD/NASH, specifically; oily fish/fish oil, coffee, nuts, tea, red wine, avocado and olive oil. Furthermore, it summarises results from animal and human trials and highlights potential areas for future research. | Vikas Gupta Xian-Jun Mah Maria Carmela Garcia Christina Antonypillai David van der Poorten | 2015 | World Journal of Gastroenterology2015，21，37： | 4 |
| 15 | Non Alcoholic Fatty Liver: Epidemiology and Natural History显示文摘 | Mario Masarone Alessandro Federico Ludovico Abenavoli Carmela Loguercio Marcello Persico | 2014 | Reviews on Recent Clinical Trials2014，，3： | 4 |
| 16 | Serum chromogranin-A in hepatocellular carcinoma: Diagnostic utility and limits显示文摘AIM: The utility of serum alpha-fetoprotein (α-FP) for the detection of hepatocellular carcinoma (HCC) is questionable.High serum levels of chromogranin-A (CgA) have recently been reported in HCC. Impaired hepatic, renal, and heart functions influence circulating CgA. The aim of this study was to assess sensitivity and specificity of serum CgA as a marker of HCC in patients with liver cirrhosis (LC).METHODS: Serum CgA levels were measured by RIA in 339 patients of which 54 HCC, 132 LC, 45 chronic hepatitis (CH), 27 chronic heart failure (CHF), 36 chronic renal failure (CRF), 45 chronic inflammatory bowel disease (IBD)as disease controls and in 75 healthy controls. Patients with liver disease or IBD and concomitant renal and/or heart failure were excluded. Pearson correlation, nonparametric combination test and confidence interval analysis were used for statistical analysis.RESULTS: Serum CgA above normal values (100 ng/mL)were found in 83% of HCC patients, in 48% of LC patients,in 20% of CH patients, in 33% of IBD patients, in 92% of CRF patients, in 100% of CHF patients, and in none of the healthy controls. The mean CgA values in HCC (769±1 046), in LC (249±369), in CH (87±94), in CRF (1 390±1 401), in CHF (577±539), in IBD (146±287) were significantly higher than those in healthy controls (48±18).HCC patients had higher CgA values (P<0.01) than LC,CH, and IBD patients but did not differ from those with CRF or CHF. The 95% CI for the mean (250-1 289 ng/mL)in HCC patients was selected as a CgA range and the lower value of such range was assumed as cut-off.Sensitivity and specificity of CgA, calculated in relation to the cut-off in patients with cirrhosis and HCC, were respectively 61% (CI 48-73%) and 82% (CI 75-88%).Serum α-FP values were >200 ng/mL in 21% of the HCC patients and in none of the LC patients. No significant correlation was found between α-FP and CgA in patients with HCC and in patients with cirrhosis.CONCLUSION: When HCC is suspected and α-FP is normal or <200 ng/mL, CgA serum values represent a complementary diagnostic tool, unless kidney or heart failure is present. | Aldo Spadaro Antonino Ajello Carmela Morace Agata Zirilli Graziella D'arrigo Carmelo Luigiano Francesco Martino Anna Bene Domenico Migliorato Santi Turiano Oscar Ferraù Maria Antonietta Freni | 2005 | World Journal of Gastroenterology2005，11，13： | 4 |
| 17 | Liver Involvement in Obese Children (Ultrasonography and Liver Enzyme Levels at Diagnosis and During Follow-up in an Italian Population)显示文摘 | Maria Carmela Saviano Francesco Brunetti Armido Rubino Adriana Franzese Pietro Vajro Alessandro Argenziano Alessandro Puzziello Maria Pina Iannucci | 1997 | Digestive Diseases and Sciences1997，，7： | 3 |
| 18 | Gastrointestinal Kaposi's sarcoma: Case report and review of the literature显示文摘Kaposi's sarcoma(KS) of the gastrointestinal tract is not an uncommon disease among individuals with acquired immunodeficiency syndrome(AIDS). The majority is asymptomatic, and for this reason, gastrointestinal KS(GI-KS) remains undiagnosed. With continued tumor growth, considerable variation in clinical presentation occurs including abdominal pain, nausea, vomiting, iron deficiency anemia(either chronic or frank gastrointestinal bleeding), and rarely mechanical obstruction alone or combined with bowel perforation. Endoscopy with biopsy allows for histological and immunohistochemical testing to confirm the diagnosis of GI-KS among those with clinical symptoms. In previous studies, dual treatment with highly active antiretroviral therapy and systemic chemotherapy have been associated with improved morbidity and mortality in individuals with visceral KS. Therefore, investigators have suggested performing screening endoscopies in select patients for early detection and treatment to improve outcome. In this review, we describe a 44 years old man with AIDS and cutaneous KS who presented for evaluation of postprandial abdominal pain, vomiting, and weight loss. On upper endoscopy, an extensive, infiltrative,circumferential, reddish mass involving the entire body and antrum of the stomach was seen. Histologic examination later revealed spindle cell proliferation, and confirmatory immunohistochemical testing revealed human herpes virus 8 latent nuclear antigen expression consistent with a diagnosis of gastric KS. Following this, we present a comprehensive review of literature on KS with emphasis on gastrointestinal tract involvement and management. | Ann Joo Lee Lacie Brenner Bashar Mourad Carmela Monteiro Kenneth J Vega Juan Carlos Munoz | 2015 | World Journal of Gastrointestinal Pharmacology and Therapeutics2015，6，3： | 2 |
| 19 | Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases显示文摘 | Carmela Loguercio Alessandro Federico Concetta Tuccillo Fulvia Terracciano Mauro Valeriano D?Auria Claudio De Simone Camillo Del Vecchio Blanco | 2005 | Journal of Clinical Gastroenterology2005，，6： | 2 |
| 20 | Accumulation of heavy metals from contaminated soil to plants and evaluation of soil remediation by vermiculite显示文摘 | Mery Malandrino Ornella Abollino Sandro Buoso Agnese Giacomino Carmela La Gioia Edoardo Mentasti | 2010 | Chemosphere2010，，2： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员